
To get the latest Acad stock quote and performance, you can check the NASDAQ stock exchange, where Acad stock is listed under the ticker symbol ACAD.
Acad stock's performance is influenced by its development of innovative treatments for various diseases, including cancer and multiple sclerosis.
The company's financial reports, available on its website, provide detailed information on its revenue, expenses, and net income.
Acad stock's stock price can fluctuate based on market conditions, investor sentiment, and company-specific events.
Discover more: S B I Card Share Price
Intriguing read: Unitech Stock Quote
Stock Performance
ACAD stock performance is a crucial aspect to consider when investing in the company. The stock has seen significant fluctuations over the years, with a 52-week high of 26.83 and a 52-week low of 14.15.
One notable fact is that the average ACADIA Pharmaceuticals stock price for the last 52 weeks is 17.51. This gives an idea of the overall trend in the stock's performance.
Here's a brief overview of ACAD's market performance:
The company's market capitalization is a significant $2.963 billion, indicating a substantial presence in the medical industry.
Stock Performance
ACADIA Pharmaceuticals stock has experienced significant fluctuations over the years, with its all-time high closing price reaching $57.00 on July 07, 2020.
The company's market value has been affected by various factors, including the FDA's response to its supplemental new drug application for Nuplazid. Despite this setback, Acadia Pharmaceuticals continues to develop innovative medicines for CNS disorders.
The stock's current market value is $2.963 billion, with a revenue of $0.726 billion. This is a significant increase from its 2008 market value of $0.9 billion.
Here are some key statistics that highlight the stock's performance:
The stock's performance has been impacted by various events, including the FDA's response to its supplemental new drug application. However, the company continues to develop innovative medicines for CNS disorders.
Empty
As we dive into the world of stock performance, it's essential to understand the earnings reports of companies like ACADIA Pharmaceuticals. Their calendar is packed with important dates, and one of the most significant events is the Q4 2024 Earnings Release.
The estimated earnings per share for this event is $0.220 USD, which is a crucial metric to keep an eye on. This figure is expected to be released on March 3rd, 2025.
ACADIA Pharmaceuticals has a history of releasing earnings reports that impact the stock market. Their Q1 2025 Earnings Release is another key event, with an estimated earnings per share of $0.029 USD, scheduled for May 13th, 2025.
Here are the upcoming earnings reports for ACADIA Pharmaceuticals, listed in chronological order:
These dates and figures will undoubtedly play a significant role in shaping the stock performance of ACADIA Pharmaceuticals.
Frequently Asked Questions
Is Acad stock a good buy?
ACAD stock is considered a good buy with a Moderate Buy consensus rating and 60.63% upside potential, based on analysts' average price target. However, it's essential to do your own research and consider multiple factors before making an investment decision.
What is the stock price forecast for Acad in 2025?
According to Wall Street analysts, Acadia Pharmaceuticals' stock price is predicted to reach $25.00 by November 7, 2025, with a potential upside of 47.49% from its current price. This forecast suggests a significant growth opportunity for investors.
What is the price target for Acadia Pharma?
The average price target for Acadia Pharmaceuticals is $25.60, representing a 47.38% potential increase from its current price of $17.37. Analysts' forecasts range from $19.00 to $42.00.
What is the stock symbol for Acadia?
The stock symbol for Acadia Pharmaceuticals is ACAD. You can find the latest information on ACAD stock price, news, and history on Yahoo Finance.
Featured Images: pexels.com


